Revive Therapeutics Ltd.

RVV

CA7615161030

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 15:18:44 2024-07-17 EDT			5-day change	1st Jan Change
0.015 ^CAD	+50.00%		+50.00%	-50.00%

07-02	Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure	CI
06-12	Revive Therapeutics Ltd. Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long Covid	CI

Revive Therapeutics Ltd.(TSXV:RVV) added to S&P/TSX Venture Composite Index

January 22, 2018 at 12:00 am

Latest news about Revive Therapeutics Ltd.

Revive Therapeutics Ltd. Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure	07-02	CI
Revive Therapeutics Ltd. Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long Covid	06-12	CI
Revive Therapeutics Ltd. Provides Update from FDA Meeting for Long Covid Diagnostic Product	06-10	CI
Revive Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-30	CI
FDA Grants Revive Therapeutics Type C Meeting Request For Bucillamine Study to Treat Long COVID	04-23	MT
Revive Therapeutics Brief: Announcing Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID	04-23	MT
Revive Therapeutics Announced FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	04-18	MT
Revive Therapeutics Brief: Announcing FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	04-18	MT
Revive Therapeutics Ltd. Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product	04-18	CI
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	04-02	MT
Revive Therapeutics Ltd. Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder	04-02	CI
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	03-27	MT
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID	03-27	CI
Revive Therapeutics to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	03-19	MT
Revive Therapeutics Ltd. Announces to Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID	03-19	CI
Revive Therapeutics Provides Corporate Update	03-12	MT
Revive Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-28	CI
Revive Therapeutics Ltd. announced that it has received CAD 2.10061 million in funding	02-25	CI
Revive Therapeutics Exploring Use of Bucillamine for Long COVID	02-01	MT
Revive Therapeutics Explores the Use of Bucillamine for Long COVID	02-01	CI
Revive Therapeutics Announces Offering of Up to $3 Million	01-25	MT
Revive Therapeutics Ltd. announced that it expects to receive CAD 3 million in funding	01-23	CI
Revive Therapeutics Ltd. Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada	01-16	CI
Revive Therapeutics Says Completed Development of a Novel Lyophilized Formulation of Bucillamine	01-10	MT
Revive Therapeutics Ltd. Successfully Completes Development of A Novel Lyophilized Formulation of Bucillamine	01-10	CI

Chart Revive Therapeutics Ltd.

Duration

Period

More charts

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Companyâs cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Sector

Biotechnology & Medical Research

Calendar

2024-10-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REVIVE THERAPEUTICS LTD.	-50.00%	3.06M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.07%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-14.81%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.34%	14.08B